OncoMatch/Clinical Trials/NCT05120596
First in Human Study of T3P-Y058-739 (T3P)
Is NCT05120596 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Pembrolizumab+T3P-Y058-739 and T3P-Y058-739 (IV) for advanced solid tumor.
Treatment: Pembrolizumab+T3P-Y058-739 · T3P-Y058-739 (IV) · T3P-Y058-739 (IT) — This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Tumor Agnostic
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
Adequate iron stores without significant iron overload
Kidney function
Liver function
Adequate iron stores without significant iron overload; Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05120596 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 74 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify